Effects of Tacrolimus combined with Glucocorticoids in treatment of patients with stage Ⅱ-Ⅲ idiopathic membranous nephropathy
Objective:To observe effects of Tacrolimus combined with Glucocorticoids in treatment of patients with stage Ⅱ-Ⅲ idiopathic membranous nephropathy(IMN).Methods:A prospective study was conducted on 84 patients with stage Ⅱ-Ⅲ IMN admitted to the hospital from June 2019 to September 2022.They were divided into control group and study group by using the odd-even number method,42 cases in each group.The control group was treated with Cyclophosphamide combined with Glucocorticoids,while the study group was treated with Tacrolimus combined with Glucocorticoids.The clinical efficacy,the 24 h proteinuria quantification,the serum total protein(ALB)level and the renal function index[serum creatinine(Scr),endogenous creatinine clearance rate(Ccr)]levels before and after the treatment,and the incidence of adverse reactions during the treatment were compared between the two groups.Results:The total effective rate of the study group was 97.62％(41/42),which was higher than 80.95％(34/42)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the 24 h urinary protein and the Scr level in the study group were lower than those in the control group,the serum ALB and Ccr levels were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Tacrolimus combined with Glucocorticoids in the treatment of the stage Ⅱ-Ⅲ IMN patients can improve the total effective rate of treatment and the ALB levels,improve the levels of renal function indexes,and reduce the 24 h urine protein quantification.Moreover,it is superior to Cyclophosphamide combined with glucocorticoid therapy.
NETL
NSTL
万方数据
